Authors:Marzieh Aligholi, Mohammad Emaneini, Morovat Taherikalani, Shadi Shahsavan, Fereshteh Jabalameli, Parisa Asadollahi, Babak Khoramian, and Mohammad Eslampour
The synergy between gentamicin and vancomycin, teicoplanin, ampicillin and linezolid was studied by time-kill method. Two clinical vancomycin resistant enterococci (VRE) and two vancomycin susceptible enterococci (VSE) isolates were used. Different concentrations of antibiotics were combined. Two VSE strains and the control strain exhibited synergism with the combination of gentamicin, vancomycin, teicoplanin, ampicillin and linezolid. Two VRE strains exhibited synergism with the combination of gentamicin and ampicillin. Synergy between gentamicin and vancomycin, teicoplanin and linezolid was not observed against these isolates. The VRE isolates were positive for vanA, aac (6′)-Ie aph (2“) and aph (3′)-IIIa genes and their vancomycin, teicoplanin and gentamicin MICs were 512 μg/ml, 512 μg/ml and >4000 μg/ml, respectively. In order to treat serious enterococcal infections, further clinical evaluation is needed to examine the in vitro combined effects of gentamicin and vancomycin, teicoplanin and linezolid.
Authors:Soraya Mousavi, Stefan Bereswill, and Markus M. Heimesaat
compounds open novel avenues for the combat of infections with emerging MDR bacterial species. However, both in vitro and in vivo (experimental and clinical) studies are needed to better understand the molecular mechanism of antimicrobialsynergies. This